导出类型

 

Nihon Rinsho 2015 Jan;73 (1): 149-55. 全文索取
[Thalidomide, cereblon and multiple myeloma].

Abstract
Cereblon was identified as a direct target of thalidomide by Prof. H. Handa, and this pioneering work triggered active research on IMiDs (immunomodulatory drugs), which include thalidomide-derivatives, such as lenalidomide and pomalidomide. These small molecules have been shown to bind to cereblon (CRBN) to modulate its activity as a substrate receptor. In addition, structural analyses on CRBN have revealed unique actions of these small agents, by which degradation of transcription factors is controlled in a specific and unique way. I summarize recent progress on CRBN-CRLA ubiquitin ligase and IMiDs, focusing on the therapeutic application of these drugs for treatment of multiple myeloma.

PMID: 25626321 [ - ]

  • Full Text Sources

关联文献

  • 加载中....

检索记录[清空]